Blood Cancer Discovery publishes high-quality Research Articles and Briefs representing major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics appropriate for coverage include but are not limited to the following: molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are characterized in animal disease models as well as in high-dimensional clinical data landscapes.
National University of Singapore (NUS) scientists have discovered that the evasion of apoptosis is a key driver of drug resistance in patients with relapsed acute myeloid leukemia (AML), a type of aggressive blood cancer. ...
Mar 19, 2024
0
0
A cellular profiling method called dynamic BH3 profiling (DBP), developed by investigators at Dana-Farber Cancer Institute, has the potential to help guide personalized treatment for relapsed, drug-resistant acute myeloid ...
Mar 6, 2024
0
0
As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients can benefit from groundbreaking therapies. In work published ...
Feb 5, 2024
0
0
Scientists previously thought mutations in myeloid genes could only cause myeloid cancers such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)—hence the name given to these genes. However, a recent study ...
Jan 29, 2024
0
0
Recent advances in treating multiple myeloma, the second most common blood cancer, and other blood malignancies are providing improved outcomes—and hope—to patients worldwide.
Jan 4, 2024
0
3
New research in Blood Cancer Discovery shows that intravenous immunoglobulin (IVIg) reduced the risk of severe infections by 90% in patients with multiple myeloma undergoing treatment with an anti-BCMA bispecific antibody.
Sep 28, 2023
0
14
